Cantor Fitzgerald Cuts Earnings Estimates for Sanara MedTech

Sanara MedTech Inc. (NASDAQ:SMTI) – Equities research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Sanara MedTech in a research note issued on Wednesday, March 26th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of ($2.43) for the year, down from their prior estimate of ($0.98). Cantor Fitzgerald currently has a “Overweight” rating and a $46.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. The business had revenue of $26.31 million for the quarter, compared to analysts’ expectations of $22.75 million. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%.

Separately, HC Wainwright increased their price target on Sanara MedTech from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday.

Sanara MedTech Stock Performance

Shares of Sanara MedTech stock opened at $30.19 on Friday. The company has a market cap of $268.75 million, a PE ratio of -30.49 and a beta of 1.37. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76. Sanara MedTech has a 52 week low of $26.00 and a 52 week high of $39.08. The business has a 50 day moving average price of $34.26 and a 200-day moving average price of $33.74.

Institutional Investors Weigh In On Sanara MedTech

A number of institutional investors have recently added to or reduced their stakes in SMTI. State Street Corp boosted its stake in shares of Sanara MedTech by 9.2% in the 3rd quarter. State Street Corp now owns 58,688 shares of the company’s stock worth $1,775,000 after buying an additional 4,932 shares during the last quarter. Barclays PLC lifted its holdings in Sanara MedTech by 323.0% during the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock worth $174,000 after acquiring an additional 4,376 shares during the period. Geode Capital Management LLC boosted its position in Sanara MedTech by 4.4% in the third quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after purchasing an additional 3,755 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Sanara MedTech by 127.2% in the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock worth $123,000 after purchasing an additional 2,272 shares during the last quarter. Finally, Fifth Third Bancorp bought a new position in Sanara MedTech in the 4th quarter valued at $898,000. 8.10% of the stock is owned by institutional investors.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.